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Abstract
Background: The fractalkine (CX3CR1) ligand is expressed in astrocytes and reported to be neuroprotective. When
cleaved from the membrane, soluble fractalkine (sCX3CL1) activates the receptor CX3CR1. Although somewhat
controversial, CX3CR1 is reported to be expressed in neurons and microglia. The membrane-bound form of CX3CL1
additionally acts as an adhesion molecule for microglia and infiltrating white blood cells. Much research has been
done on the role of fractalkine in neuronal cells; however, little is known about the regulation of the CX3CL1 ligand
in astrocytes.
Methods: The mechanisms involved in the up-regulation and cleavage of CX3CL1 from human astrocytes were
investigated using immunocytochemistry, Q-PCR and ELISA. All statistical analysis was performed using GraphPad
Prism 5.
Results: A combination of ADAM17 (TACE) and ADAM10 protease inhibitors was found to attenuate IL-1β-,
TNF-α- and IFN-γ-induced sCX3CL1 levels in astrocytes. A specific ADAM10 (but not ADAM17) inhibitor also
attenuated these effects, suggesting ADAM10 proteases induce release of sCX3CL1 from stimulated human
astrocytes. A p38 MAPK inhibitor also attenuated the levels of sCX3CL1 upon treatment with IL-1β, TNF-α or
IFN-γ. In addition, an IKKβ inhibitor significantly reduced the levels of sCX3CL1 induced by IL-1β or TNF-α in a
concentration-dependent manner, suggesting a role for the NF-kB pathway.
Conclusions: In conclusion, this study shows that the release of soluble astrocytic fractalkine is regulated by
ADAM10 proteases with p38 MAPK also playing a role in the fractalkine shedding event. These findings are
important for understanding the role of CX3CL1 in healthy and stimulated astrocytes and may benefit our
understanding of this pathway in neuro-inflammatory and neurodegenerative diseases.
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Background
The chemokine fractalkine (CX3CL1) is expressed in the
central nervous system (CNS) at relatively high levels in
comparison to most other cytokines [1]. CX3CL1 is a
transmembrane protein with a chemokine domain at-
tached to a mucin-like stalk [2]. Although somewhat
controversial, over the years, it has been shown that the
CX3CL1 chemokine is expressed primarily on neurons
and astrocytes, with its receptor, CX3CR1, expressed on
microglia and neurons [1, 3–8]. Therefore, neurons and
astrocytes can signal to neurons and microglia express-
ing CX3CR1. CX3CL1 can exist in two different forms
with the membrane-bound form important for adhesion
[9]. CX3CL1 can also be cleaved by ADAM10, ADAM17
or cathepsin S, depending on the cell type and the
microenvironment [10, 11]. This cleavage from the cell
surface of neurons or astrocytes mainly represents a re-
sponse to insult or injury. Within the CNS, CX3CL1 has
potential to be both neuroprotective and toxic [7, 12–15].
The exact roles for either form of CX3CL1 within the
CNS are not completely understood, but in general,
because of the high levels in the adult brain, CX3CL1
is thought to help maintain a homeostatic environ-
ment as well as respond to CNS insults [4, 5, 16].
Studies also suggest that tonic signalling of the
CX3CL1 ligand has an anti-inflammatory effect by
somewhat controlling microglial activation states. There-
fore, inhibition of this tonic signalling may support inflam-
matory processes [17].
Transmembrane proteins, such as CX3CL1, can be
proteolytically cleaved at the juxtamembrane region,
which results in the detachment of their extracellular re-
gion (ectodomain) in a process known as ectodomain
shedding [18]. This shedding process can release pro-
teins such as cytokines and growth factors from their
membrane-bound form, or alternatively, it can down-
regulate receptors from the cell surface [18]. Proteases
such as the matrix metalloprotease (MMP) family shed
several cell surface substrates [19, 20]. One such family
of metalloproteases that mediate these events are known
as ADAMs (a disintigrin and metalloprotease), of which
the tumour necrosis factor alpha (TNF-α)-converting
enzyme (TACE/ADAM17) and ADAM10 are most stud-
ied [21, 22]. Much work has been done on ADAMs in
the periphery, as they are highly abundant in many cell
types [11]. Previous studies suggest ADAM17 as the pri-
mary protease responsible for inducible cleavage of fractalk-
ine in neurons, with ADAM10 playing a role in constitutive
CX3CL1 cleavage [12, 23, 24]. Recent findings suggest that
altered function of ADAM10 could contribute to neurode-
generative disease processes such as Alzheimer’s disease
and encephalopathies [25, 26]. Importantly, this shedding
process of CX3CL1 can be activated by cytokines and
growth factors via mitogen-activated protein kinase
(MAPK) pathways that involve, among others, p38 sig-
nalling [27–30].
Widespread ADAM expression has been demonstrated
in the CNS, where a number of previous studies have
suggested the expression of ADAM10 and ADAM17 in
astrocytes [31]. For example, immunolabelling has re-
vealed increased expression of ADAM10 and ADAM17
associated with reactive astrocytes in murine dentate gyrus
[32]. ADAM10 has also been found to be increased in im-
munohistochemical studies of HIV encephalitis clinical
samples in both astrocytes and neurons [33]. Carnosic acid
treatment is reported to enhance the messenger RNA
(mRNA) expression of ADAM17 in human astrocytoma
cells [34], and IL-1α stimulates ADAM17 synthesis in hu-
man primary astrocytes [27]. Interleukin-1 beta (IL-1β),
TNF-α and interferon gamma (IFN-γ) are archetypical
pro-inflammatory mediators, and studies have also re-
ported the expression and activation of receptors for IL-1β
[35, 36] and TNF-α on human astrocytes [37]. Human as-
trocytes have also been shown to produce Aβ40 and Aβ42
when stimulated with IFN-γ and TNF-α or IL-1β [38]. In
addition, human and murine astrocytes treated with IFN-γ
induced CXCL10 [39]. These cytokines have also been
previously shown to increase fractalkine expression on as-
trocytes [6, 29, 40]. Others and we have also shown previ-
ously that human astrocytes respond to these cytokines
[41]. We note also that IL-1β and TNF-α signal primarily
via nuclear factor kappa b (NF-kB) [37, 42, 43] while IFN-
γ signals largely through JAK/STAT [44, 45] allowing for
the investigation of two differential pathways.
Many studies performed on peripheral cells implicate
ADAM10 in the constitutive shedding of the CX3CL1
ligand from various cell types, while ADAM17 is thought
to be the main protease regulating inducible cleavage of
this ligand [23]. While a low level of CX3CL1 expression
in astrocytes has been reported [3], little information cur-
rently exists regarding its regulation, constitutive shedding
or inducible cleavage in this cell type. Here, we present
new data examining cytokine (IL-1β, TNF-α and IFN-γ)-




Inhibitors used ADAM10/ADAM17 inhibitor (BMS-
561392), specific ADAM17 inhibitor (BMS-566394), spe-
cific ADAM10 inhibitor (TOCRIS; GI 254023X), MMP in-
hibitor (Millipore; 444289), IKKβ inhibitor (TOCRIS; 2559)
and the p38 MAPK inhibitor VX-702 (TOCRIS; 3916) were
prepared as 10 mM stock solutions dissolved in 90 % di-
methyl sulfoxide (DMSO, Sigma; D8418). The cytokines
used were interleukin-1β (IL-1β; R&D Systems, PHC0815),
tumour necrosis factor α (TNF-α; R&D Systems, 210-TA)
and interferon-γ (IFN-γ; GIBCO, PHC4031).
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Human astrocyte cell culture
Human astrocytes from fetal brains were purchased from
ScienCell Research Laboratory, USA (1800, Lot Nos. 9063
and 11065), as per the ethics outlined by the supplier and
as we have described previously [41, 46–48]. Human
astrocytes were cultured at 37 °C and 5 % CO2 in a hu-
midified incubator and grown in human astrocyte spe-
ciality media (ScienCell; 1801) or standard DMEM/F12
media (Fisher; 10770245) supplemented with 1 % astro-
cyte growth supplement (ScienCell; 1852), 10 % fetal
bovine serum (FBS, Sigma; F7524) and 1 % penicillin/
streptomycin (pen/strep, Sigma; P4333) in T75 culture
flasks (Corning) unless otherwise indicated in the figure
legends. Given human astrocyte speciality media were ap-
proximately twice the cost of the standard cell culture
media with supplements, we assessed the levels of
sCX3CL1 using both media, with the only difference being
the base media. Variations in the levels of sCX3CL1 re-
leased from the astrocytes between experiments can be
primarily attributed to this reason and are highlighted ac-
cordingly in the figure legends. The cells were grown for
14 days until 90 % confluent and then re-plated in six- or
24-well plates and used when 80 % confluent.
Quantitative polymerase chain reaction (Q-PCR)
For mRNA expression of CX3CL1, human astrocytes
were grown in six-well plates until 80 % confluent. Prior
to stimulation, cells were starved in serum-free media
for 3 h. The cells were then pre-treated with either VX-
702 (p38 inhibitor) or an IKKβ inhibitor in serum-free
media for 30 min, after which IL-1β, TNF-α or IFN-γ
was added and incubated for 3 or 18 h. After treatment,
the media were removed and cells were washed twice
with phosphate-buffered saline (PBS) in preparation for
Q-PCR analysis. RNA extraction was performed using
either Qiagen or Macherey-Nagel methods as described
by the manufacturers. Using Qiagen kits, the cell pellets
were suspended in RLT lysis buffer (Qiagen Hilden,
Germany) and then frozen at −80 °C. RNA was isolated
using RNeasy mini kit (Qiagen, 74104). To eliminate
genomic DNA, an on-column DNase digestion was car-
ried out with the RNase-free DNase set (Qiagen 79254).
After reverse transcription of mRNA (10 min at 25 °C;
120 min at 37 °C; 5 s at 85 °C) using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
4368814), RT-PCR was performed with the 7900HT Fast
Real-Time PCR System (Applied Biosystems, 4329001)
according to the Standard Thermal Cycler Protocol
(2 min at 50 °C; 10 min at 95 °C; 40 cycles of 15 s at 95 °C
and 1 min at 60 °C). The threshold was set manually for all
samples. The analysis was performed with the SDS 2.3 soft-
ware. For the Macherey-Nagel method (Macherey-Nagel;
740955), cells were suspended in RA1 buffer with 1 % beta-
mercaptoethanol and frozen at −80 °C. To eliminate
genomic DNA, an on-column DNase digestion was carried
out with the RNase-free DNase. After reverse transcription
of mRNA (10 min at 25 °C; 120 min at 37 °C; 5 s at 85 °C)
using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, 4368814), RT-PCR was performed
according to the Standard Thermal Cycler Protocol
(2 min at 50 °C; 10 min at 95 °C; 40 cycles of 15 s at
95 °C and 1 min at 60 °C). TaqMan Gene Expression As-
says using TaqMan probes of human CX3CL1 (Applied
Biosystems; Hs00171086_M1) and HPRT (Applied Biosys-
tems; Hs01003267_M1) (all FAM dye labelled) were used.
The relative expression of CX3CL1 to the reference gene
HPRT was determined. Each condition was run in tripli-
cates, and the experiments were repeated independently
three times unless otherwise indicated in the figure legends.
Enzyme-linked immunosorbent assay (ELISA)
All cells were starved in serum-free media before treat-
ments. Human astrocytes were pre-treated with inhibitors
for 30 min followed by 18-h treatment with cytokines as
indicated in the figure legends. Media were then collected,
and cells were lysed in PTxE lysis buffer (1 mM EDTA
and 1 % Triton-X in PBS) and frozen at −20 °C. Soluble
fractalkine (sCX3CL1) levels in the supernatant and total
cellular content were measured with human CX3CL1
ELISA kit according to the manufacturer’s instructions
(R&D Systems; DY365). This DuoSet detects the N-
terminal chemokine domain of human fractalkine. The
level of detection for fractalkine indicated by the manufac-
turers is 0.63–20 ng/ml, although we noted significant and
detectable changes in colour at lower levels. Briefly, 96-
well ELISA plates (Thermo Scientific; 95029780) were
coated overnight at room temperature with capture anti-
bodies diluted in PBS. The plates were washed three times
with wash buffer (0.05 % Tween 20 (Sigma; P7949), PBS,
pH 7.4) and then blocked for 1 h at room temperature
with the appropriate reagent diluent. The plates were then
washed three times with wash buffer, and any remaining
buffer was removed from the wells by aspiration. A stand-
ard curve was prepared using serial dilutions of the re-
combinant protein diluted in the appropriate reagent
diluents. The samples and standards were then incubated
in the antibody-coated ELISA plate for 2 h at room
temperature. The plate was then washed three times with
wash buffer, and detection antibody (diluted in reagent di-
luent) was added to each well for 2 h. Following three
more washes, streptavidin-HRP diluted in reagent diluents
was added to each well and incubated for 20 min at room
temperature, protected from light. After an additional
three washes, the wells were incubated with substrate so-
lution (R&D systems; DY999) for 15 min at room
temperature protected from light. The colour reaction was
stopped with the addition of 1 M H2SO4, and absorbance
was read immediately using a plate reader at 450 nm
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(Labsystem Multiskan). The standard curve was calculated
by plotting the standards against the absorbance values,
and the cytokine levels were measured in pg/ml.
Immunocytochemistry
Human astrocytes were plated on glass coverslips in six-
well plates (VWR) and cultured for at least 24 h until
80 % confluent. The cells were then washed with PBS
and fixed with 4 % paraformaldehyde (PFA) for 10 min
at room temperature. Permeabilization and nonspecific
binding was reduced by incubating cells for 1 h at room
temperature in blocking buffer (PBS supplemented with
1 % bovine serum albumin (BSA) and 0.1 % Triton-X
100). For all antibody incubation and wash steps, diluted
blocking buffer (PBS supplemented with 0.5 % BSA and
0.01 % Triton-X 100) was used. The cells were incubated
overnight at 4 °C with the rabbit anti-CX3CL1, which binds
the N-terminal chemokine domain (1:500, eBioscience;
14-7986); washed three times; and incubated with anti-
rabbit secondary antibody conjugated to Alex488 (1:1000;
Invitrogen; A11008) for 1 h. After washing three times in
PBS supplemented with 0.01 % Triton-X 100, the cells
were then incubated with Hoechst nuclear stain (diluted
1:10,000 in PBS)(Invitrogen; H21486) for 10 min and
washed twice again. The coverslips were then mounted on
glass slides in Vectashield (Vector Labs) and the edges
sealed with varnish. Samples were stored at 4 °C in the
dark until imaged. The cells were visualized with a con-
focal microscope (Leica SP8).
Statistical analysis
All statistical analysis was performed using GraphPad
Prism 5. In experiments where three or more groups
were compared, an ordinary one-way analysis of variance
(ANOVA) was performed and was followed by post hoc
tests. Tukey’s post hoc test was used for experiments
where all columns were compared to each other.
Student’s t test was used to compare the means be-
tween two groups. Detailed data analysis methods
are provided in the “Methods” section, figure legends
and “Results” section.
Results
CX3CL1 release from human astrocytes is stimulated by
pro-inflammatory cytokines
As a result of the low expression of CX3CL1 on astrocytes,
its functional expression has not been well characterized to
date. In agreement with previous observations [3, 6], astro-
cytes showed little to no release of sCX3CL1 into the media
after 6 and 36 h of serum starvation, suggesting minimal
surface expression and subsequent cleavage of CX3CL1
under basal conditions (data not shown). In contrast, the
treatment of human astrocytes with IL-1β induced a con-
centration- and time-dependent increase in the levels of
sCX3CL1 (Fig. 1a). Specifically, human astrocytes treated
with IL-1β for 6 h showed no significant increase in the
levels of sCX3CL1, whereas 18-h treatment with IL-1β at
1 pg/ml (220.5 ± 17.5), 10 pg/ml (711.8 ± 12.8) and 100 pg/
ml (911.5 ± 10.0) significantly increased the levels of
sCX3CL1 (Fig. 1a). Immunocytochemistry also showed the
treatment of human astrocytes with IL-1β (100 pg/ml),
TNF-α (10 ng/ml) or IFN-γ (10 ng/ml) increased the levels
of CX3CL1 in human astrocytes, using an antibody di-
rected against the chemokine N-terminal domain of
CX3CL1 (eBioscience; 14-7986) (Fig. 1b). In these ex-
periments, under control conditions, we noted little to
no cellular expression of fractalkine, in agreement
with the ELISA data. Treatment with the cytokines,
IL-1β, TNF-α and IFN-γ, increased the levels of frac-
talkine that appeared within the cell, with no evident
appearance at the cell membrane. We propose that
rapid shedding of fractalkine once it reaches the mem-
brane may result in a low/no detection of fractalkine
at the cell membrane. In support, we also examined
the levels of fractalkine in the cell and found that
treatment with the cytokines, IL-1β, TNF-α and IFN-γ,
increased significantly the levels of fractalkine in the
cell lysates (Fig. 1c). This data is in line with other
studies suggesting low levels of fractalkine in astrocytes
under basal conditions, which increases with inflammatory
stimuli [6, 40].
IL-1β, TNF-α and IFN-γ increase the levels of CX3CL1
mRNA
To determine whether IL-1β, TNF-α and IFN-γ alter
the levels of CX3CL1 by increasing protein synthesis,
we examined their effect on CX3CL1 mRNA using
Q-PCR (Fig. 2a). Treatment of human astrocytes with
IL-1β (100 pg/ml, Fig. 2b), TNF-α (10 ng/ml, Fig. 2c)
and IFN-γ (10 ng/ml, Fig. 2d), for 3 h, significantly
increased the levels of CX3CL1 mRNA in all three
cases, by 20-fold or more. These effects appeared
transient in so far as cytokine treatment for 18 h in-
creased the levels of CX3CL1 mRNA but not to the
same extent as 3 h. In particular, IL-1β treatment sig-
nificantly increased the levels of CX3CL1 mRNA but
only by approximately twofold (Fig. 2e), and treat-
ment for 18 h with TNF-α increased the levels of
CX3CL1 mRNA by approximately fivefold compared
to control (Fig. 2f ). As an additional note, we con-
firmed these cytokines did not cause cell death using
MTT assays and noted IL-1β and TNF-α caused a modest
increase in cell viability (Additional file 1: Figure S1B).
Overall, these results show that the cytokines IL-1β, TNF-
α and IFN-γ increase the expression of CX3CL1 by likely
promoting mRNA and protein synthesis, without overtly
affecting cell survival.
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Matrix metalloprotease inhibitors attenuate IL-1β-, TNF-α-
and IFN-γ-induced levels of CX3CL1 in human astrocytes
Matrix metalloproteases (MMPs) are a family of proteases
that are capable collectively of degrading proteins in the
extracellular matrix (ECM). MMPs are also involved in
the cleavage of cell surface receptors and ligands such as
cytokines and chemokines [49]. Thus, MMPs can play im-
portant roles in regulating cellular processes such as cell
death and inflammation [49]. Notably, however, the ability
of MMPs to cleave the CX3CL1 ligand is less well studied
in glial cells, particularly in astrocytes. To determine
whether MMPs play a role in the release of the CX3CL1
ligand from human astrocytes, the soluble levels of
CX3CL1 were measured in astrocyte-conditioned media
using ELISA. Human astrocytes were pre-treated with a
pan MMP inhibitor, RS-130830 (1 μM for 30 min), prior
to 18-h treatment with the pro-inflammatory stimuli; IL-
1β (100 pg/ml), TNF-α (10 ng/ml) or IFN-γ (10 ng/ml).
Treatment with IL-1β (1328.0 ± 253.8) (Fig. 3a), TNF-α
(2185.0 ± 113.3) (Fig. 3b) and IFN-γ (1687 ± 181.2) (Fig. 3c)
increased the levels of sCX3CL1 after 18 h, compared to
control (###p < 0.001 n = 3; one-way ANOVA and Tukey’s
post hoc test). Importantly, pre-treatment with a pan
MMP inhibitor, RS-130830, attenuated the CX3CL1-
induced increase by IL-1β (666.8 ± 46.8; **p < 0.01), TNF-α
(1207.0 ± 108.4; ***p < 0.001) and IFN-γ (821.0 ± 110.9; *p
< 0.05), respectively, compared to the matched treated
group (one-way ANOVA and Tukey’s post hoc test)
(Fig. 3a–c). Notably, the MMP inhibitor, RS-130830, had
no effect on cell viability (Additional file 1: Figure S1C).
These results suggest that human astrocytes shed the
CX3CL1 chemokine in response to IL-1β, TNF-α and
IFN-γ and that pre-treatment with a pan MMP inhibi-
tor significantly reduces this response.
ADAM10 inhibitor reduces pro-inflammatory cytokine-
mediated increase of CX3CL1 in human astrocytes
ADAM10 and ADAM17 proteases have also been impli-
cated in the cleavage of CX3CL1 from the cell surface of
ECV-304 cells and fibroblasts, with ADAM10 involved
in constitutive shedding of the ligand [23, 30]. To our
knowledge, it is unknown whether the same proteinases
are used to cleave the CX3CL1 on astrocytes. We again
noted low levels of CXC3L1 in conditioned media taken
from human astrocytes, suggesting low levels of expres-
sion in these cells under control conditions and which
Fig. 1 Soluble fractalkine (sCX3CL1) release from human astrocytes. a Human astrocytes (grown in speciality media) were treated with IL-1β
(1 pg/ml, 10 pg/ml and 100 pg/ml) for 6 or 18 h, and the levels of sCX3CL1 in the media were quantified by ELISA. The levels of CX3CL1 were
significantly higher after 18-h treatments compared to 6 h. All values expressed as averages ± SEM; n = 4, each condition done in duplicate.
One-way ANOVA and Tukey’s post hoc test; ***p < 0.001 compared to control. b Immunostaining of up-regulated CX3CL1 on human astrocytes (grown
in speciality media) when treated with IL-1β (100 pg/ml), TNF-α (10 ng/ml) and IFN-γ (10 ng/ml) for 18 h. c Quantification of total cellular content of
CX3CL1 following cytokine stimulation. Human astrocytes (grown in standard media) were treated with a IL-1β (100 pg/ml), TNF-α (10 ng/ml) and
IFN-γ (10 ng/ml) for 18 h. Following stimulation, cells were lysed with PTxE lysis buffer and the levels of sCX3CL1 were quantified by ELISA. Data
presented as mean ± SEM, n = 4, unpaired t test, *p < 0.05, ***p < 0.001 vs. corresponding control. In all cases, cells were serum starved 3 h
before treatments
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also suggests the amount of constitutive shedding from
human astrocytes is low. Next, to investigate whether
ADAM10 and/or ADAM17 proteases are involved in the
inducible shedding of CX3CL1 from human astrocytes
under stimulated conditions, these cells were pre-treated
for 30 min with the dual ADAM10/ADAM17 (BMS-
561392) inhibitor, the selective ADAM17 inhibitor
(BMS-566394) or the selective ADAM10 inhibitor
(TOCRIS; GI 254023X) before treatment with the pro-
inflammatory recombinant cytokines, IL-1β (100 pg/ml),
TNF-α (10 ng/ml) or IFN-γ (10 ng/ml). As expected, IL-
1β (84.6 ± 8.7, Fig. 4a), TNF-α (400.6 ± 63.06, Fig. 4b) and
IFN-γ (163.5 ± 49.05, Fig. 4c) significantly increased the
levels of CX3CL1 (###p < 0.001 compared to control). Im-
portantly, pre-treatment with the ADAM10/ADAM17
dual inhibitor significantly decreased the levels of CX3CL1
induced by IL-1β (663.7 ± 39.5, Fig. 4a), TNF-α (600.3 ±
30.2, Fig. 4b) and IFN-γ (847.8 ± 146.6, Fig. 4c) (***p <
0.001, **p < 0.01 compared to the matched treated group).
In contrast, the selective inhibitor for ADAM17 did not
alter the levels of CX3CL1 induced by IL-1β (973.5 ± 64.3,
Fig. 4d), TNF-α (944.2 ± 39.0, Fig. 4e) and IFN-γ (1776.0 ±
129.3, Fig. 4f). However, the specific ADAM10 inhibitor
also attenuated the IL-1β (84.5 ± 8.7 vs. 32.0 ± 5.0, Fig. 4g),
TNF-α (401.0 ± 63.1 vs. 115 ± 36.0, Fig. 4h) and IFN-γ
(163.5 ± 49.1 vs. 47.9 ± 8.6, Fig. 4i) induced levels of
sCX3CL1 (**p < 0.01, *p < 0.05 compared to the matched
treated group). During our experiments, we noted vari-
ations in the absolute levels of CX3CL1, between ex-
periments. These can be linked to the different batches
of human astrocytes used, the age/passage number of
these cells and the use of speciality or standard media.
Importantly, however, while the absolute levels of CX3CL1
differed between experiments, the effects of the cytokines
Fig. 2 IL-1β, TNF-α and IFN-γ induce CX3CL1 mRNA synthesis in human astrocytes. a Experimental timeline and treatments are shown. Human
astrocytes were serum starved for 3 h prior to stimulation with b, e IL-1β (100 pg/ml), c, f TNF-α (10 ng/ml) or d IFN-γ (10 ng/ml) for either 3 h (grown
in standard media) or 18 h (grown in speciality media). All graphs show significant increase in CX3CL1 mRNA levels after 3 and 18 h. Data presented
as mean ± SEM, n = 4–8, unpaired t test, *p < 0.05, ***p < 0.001 vs. corresponding control
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IL-1β, TNF-α and IFN-γ were similar as the effects of the
inhibitors used. To convince ourselves further of a role for
ADAM10 in the inducible increase in the levels of
CX3CL1, we replicated experiments examining the effects
of the ADAM10 inhibitor by co-stimulating astrocytes
with TNF-α and IFN-γ (1 ng each). In this experiment, we
still found that the ADAM10 inhibitor significantly
attenuated TNF-α/IFN-γ-induced levels of fractalkine
(19,948 ± 2357 vs. 5208 ± 1569) (Additional file 1:
Figure S1A) (***p < 0.001, compared to the matched
treated group). The effects of this ADAM10 inhibitor
were also not associated with any significant changes
in cell viability (Additional file 1: Figure S1C). Of
interest, we also examined the effect of IL-1β, TNF-
α and IFN-γ on the expression levels of ADAM10 in
human astrocytes and found they did not alter the
levels of either the pro- or active form of ADAM10
(Additional file 1: Figure S1D). Taken together, these
data suggest ADAM10 plays a central role in the
shedding of CX3CL1 from astrocytes and that the
cytokines IL-1β, TNF-α and IFN-γ likely alter the
enzymatic activity of ADAM10, rather than altering
its level of expression, per se.
Inhibition of the p38 MAP kinase attenuates IL-1β-,
TNF-α- and IFN-γ-induced levels of sCX3CL1
Previous studies have demonstrated that the cytokines
IL-1β, TNF-α and IFN-γ alter the levels of p38 in astro-
cytes [37, 44, 50–53]. The p38 inhibitor, VX-702, has
been extensively used in the literature. VX-702 has been
validated as a p38 inhibitor and has been clinically evalu-
ated for the treatment of chronic inflammatory disorders
(ClinicalTrials.gov Identifier NCT00395577) [54, 55].
Several studies have shown that p38 MAP kinase
(MAPK) is required for phosphorylation and activation
of ADAM10 and ADAM17 in peripheral cells [27, 30].
Therefore, to investigate if IL-1β, TNF-α and IFN-γ pro-
mote cleavage of CX3CL1 via a p38 MAPK-dependent
pathway, we tested if the p38 MAPK inhibitor, VX-702
(TOCRIS; 3916), attenuated the increase of CX3CL1
levels induced by these pro-inflammatory cytokines. Hu-
man astrocytes were serum starved for 3 h prior to pre-
treatment with the p38 inhibitor, VX-702 (1 μM; 30 min),
and then incubated with IL-1β (100 pg/ml), TNF-α (10 ng/
ml) or IFN-γ (10 ng/ml) for 18 h. In line with previous data
[29, 56], the p38 MAPK inhibitor attenuated the IL-1β
(2552 ± 91.18 vs. 1254 ± 36.46) (Fig. 5a), TNF-α (1475 ±
91.7 vs. 969.7 ± 49.07) (Fig. 5b) and IFN-γ (2033 ± 187.6 vs.
1118 ± 231.6) (Fig. 5c) induced levels of sCX3CL1 (***p <
0.001, **p < 0.01, compared to the matched treated group),
without causing any changes in cell viability (Additional
file 1: Figure S1C). This data may be likely explained by
a required phosphorylation, preceding an ADAM10-
mediated shedding of CX3CL1 from human astrocytes.
Fig. 3 Inhibition of matrix metalloprotease’s attenuates sCX3CL1 release
from human astrocytes. Human astrocytes (grown in speciality media)
were pre-treated with a pan MMP inhibitor (MMP inhib.) Marimastat
(1 μM) for 30 min. Cells were then stimulated with either a IL-1β
(100 pg/ml), b TNF-α (10 ng/ml) or c IFN-γ (10 ng/ml) for 18 h. All groups
were serum starved 3 h before treatments. Quantification of CX3CL1
ELISA revealed a significant decrease in CX3CL1 when cells were pre-
treated with Marimastat for all treatment groups. ###p< 0.001 compared
to own control; ***p< 0.001 and **p< 0.05 compared to the matched
treated group. All values expressed as averages ± SEM; n= 3–5, each
condition done in duplicate (one-way ANOVA and Tukey’s post hoc test)
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IKKβ inhibitor attenuates pro-inflammatory cytokine-
induced protein levels of CX3CL1 in human astrocytes
The transcription factor NF-kB regulates the production
of several pro-inflammatory cytokines [57]. Reciprocally,
the cytokines IL-1β, TNF-α and IFN-γ alter NF-kB sig-
nalling [37, 42, 43, 53]. Thus, in order to further investi-
gate the mechanism by which pro-inflammatory cytokines
increase CX3CL1 levels in human astrocytes, effects of the
NF-kB pathway inhibitor IKKβ (TPCA-1) were examined
on the protein levels of CX3CL1 using ELISA. Human
astrocytes were serum starved for 3 h before 30-min
pre-treatment with the IKKβ (TPCA-1, 3, 1, 0.3, 0.1
and 0.03 μM) inhibitor, prior to the addition of IL-1β
(100 pg/ml) or TNF-α (10 ng/ml) for 18 h. As demon-
strated previously, IL-1β and TNF-α increased the
levels of CX3CL1, which were significantly attenuated by
the IKKβ inhibitor (TPCA-1, using 1 μM, 628.3 ± 138.5 vs.
47.7 ± 14.9 for IL-1β; 748.0 ± 120.0 vs. 116.4 ± 31.7 for
TNF-α) (Fig. 6) (###p < 0.001 compared to own control;
**p < 0.01 and ***p < 0.001 compared to the matched
treated group). From this data, we conclude that the pro-
inflammatory cytokines IL-1β and TNF-α increase the
levels of sCX3CL1 by promoting NF-kB-dependent
synthesis which results in subsequent enhanced shedding
of CX3CL1 via an ADAM10-dependent mechanism.
Discussion
Summary of findings
In the current study, we investigated fractalkine (CX3CL1)
expression and regulation in human astrocytes. We
showed firstly that CX3CL1 is expressed in human as-
trocytes and is constitutively shed at low levels. On
stimulation with pro-inflammatory cytokines such as
IL-1β, TNF-α and IFN-γ, this low level of sCX3CL1 is
significantly up-regulated. We noted that a broad-spectrum
MMP inhibitor attenuated this increase in CX3CL1.
Using a dual inhibitor of ADAM10/ADAM17 and se-
lective ADAM10 and ADAM17 inhibitors, we showed
further that ADAM10 is the main protease responsible
for the cytokine-mediated inducible shedding of sCX3CL1.
We also found these cytokines stimulated the mRNA
levels of CX3CL1 suggesting a mechanism involving in-
creased mRNA and protein synthesis. Using a p38 MAPK
inhibitor, we demonstrated that the pro-inflammatory
cytokine-mediated increase in sCX3CL1 likely involved
a phosphorylation event mediated by p38 MAPK. An
Fig. 4 ADAM10 inhibitor attenuates IL-1β-, TNF-α- and IFN-γ-induced sCX3CL1 release. Human astrocytes (a–f grown in speciality media, g–i
grown in speciality media) were serum starved for 3 h and pre-treated with a combination of the ADAM10/17 inhibitor (BMS-561392; 1 μM),
specific TACE inhibitor (BMS-566394; 1 μM) or specific ADAM10 inhibitor (GI 254023X; 1 μM) for 30 min. Cells were then stimulated with either
IL-1β (100 pg/ml) (a, d, g), TNF-α (10 ng/ml) (b, e, h) or IFN-γ (10 ng/ml) (c, f, i) for 18 h. Quantification of CX3CL1 ELISA revealed a significant
decrease in sCX3CL1 when pre-treated with the ADAM10/17 inhibitor and specific ADAM10 inhibitor. No significant difference was seen with the
specific ADAM17 inhibitor. ###p < 0.001 compared to own control; *p < 0.05, **p < 0.01 and ***p < 0.001 compared to the matched treated group.
Values expressed as averages ± SEM; n = 4–8, each condition done in duplicate (one-way ANOVA and Tukey’s post hoc test)
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inhibitor of IKKβ also attenuated the increase in sCX3CL1
induced by the pro-inflammatory cytokines IL-1β and
TNF-α, suggesting involvement of the NF-kB pathway.
Taken together, the data indicates that pro-inflammatory
cytokines regulate CX3CL1 expression on human astro-
cytes and that ADAM10 is the main protease involved in
the liberation of sCX3CL1 from human astrocytes.
ADAM10 regulates cytokine-mediated levels of sCX3CL1
in astrocytes
Both ADAM10 and ADAM17 have been implicated in
the development of neurodegenerative diseases such
as Alzheimer’s disease [25, 58, 59]. Studies have also
shown that ADAM10 expression is widespread in the
CNS compared to a more restricted ADAM17 expression
[31]. A more ubiquitous expression of ADAM10 would
suggest this enzyme may be responsible for the constitutive
Fig. 5 The p38 inhibitor (VX-702) reduces IL-1β-, TNF-α- and IFN-γ-
induced sCX3CL1 release. Human astrocytes (grown in speciality
media) were serum starved for 3 h and pre-treated with the p38
inhibitor, VX-702 (1 μM), for 30 min. Cells were then stimulated with
either a IL-1β (100 pg/ml), b TNF-α (10 ng/ml) or c IFN-γ (10 ng/ml)
for 18 h. Quantification of CX3CL1 ELISA revealed a significant
decrease in sCX3CL1 when pre-treated with VX-702 for all treatment
groups. ###p < 0.001 compared to own control; ***p < 0.001 and
**p < 0.01 compared to the matched treated group. Values expressed
as averages ± SEM; n = 3, each condition done in duplicate (one-way
ANOVA and Tukey’s post hoc test)
Fig. 6 IKKβ inhibitor attenuates sCX3CL1 release. Human astrocytes
(grown in speciality media) were serum starved for 3 h and pre-treated
with the NF-kB inhibitor, TPCA-1 (IKKβ inhib.; 3, 1, 0.3, 0.1 and 0.03 μM),
for 30 min. Cells were then stimulated with either IL-1β (100 pg/ml) or
TNF-α (10 ng/ml) for 18 h. Quantification of CX3CL1 ELISA revealed a
concentration-dependent decrease in sCX3CL1 release for both
IL-1β- and TNF-α-treated groups. ###p < 0.001 compared to own
control; **p < 0.01 and ***p < 0.001 compared to the matched treated
group. Values expressed as averages ± SEM; n = 3 each condition done
in duplicate. (one-way ANOVA and Tukey’s post hoc test)
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basal processing of ligands such as CX3CL1 [31, 59]. In
contrast, a low expression of ADAM17 appears to coin-
cide with its proposed involvement in inducible proteo-
lytic processing. For example, previous studies show that
pro-inflammatory cytokines, such as CXCL12, can regu-
late cleavage of the CX3CL1 ligand from neurons [12].
The treatment of neurons with CXCL12 stimulates the ex-
pression of ADAM17 causing an increase in sCX3CL1
[12]. Studies also show that ADAM10 is responsible for
constitutive neuronal CX3CL1 cleavage [23]. In contrast,
our studies on human astrocytes would suggest that
ADAM10 is responsible for the cytokine-mediated pro-
teolytic processing of sCX3CL1. In support of our
findings, siRNA knockdown of ADAM-10 (but not
ADAM17), in a human adult brain endothelial cell line,
was shown to significantly reduce sCX3CL1, following
pro-inflammatory cytokine treatment [60]. This finding
raises the possibility that differential regulation of
ADAM10 and ADAM17 may be cell type dependent
and provide a mechanism for regulating different cellu-
lar responses to the same stimuli.
Involvement of p38 MAPK in the regulation of ADAM10
Similar to studies investigating the release of CX3CL1
from neurons, we show here that the shedding of
CX3CL1 occurs both constitutively and in response to
inflammatory stimuli in astrocytes [23, 30]. We find, in
particular, that ADAM10 likely regulates pro-inflammatory
cytokine-induced levels of CX3CL1 in astrocytes. Notably,
several other ligands are shed by ADAM10, such that cleav-
age by this protease is likely controlled by multiple regula-
tory mechanisms [61]. The cytosolic tail of ADAM10, as
well as other ADAM proteases, contains many interaction
motifs for signalling and adapter proteins, which could con-
ceivably regulate protease activity [61]. Indeed, studies have
shown that downstream signalling molecules such as p38
interact with the cytoplasmic domain of ADAM10 and
regulate ADAM-dependent ligand shedding [28, 30, 62].
Popular thought is that constitutive shedding is governed
by p38 [61, 63]. In neurons, it appears that p38 regu-
lates the constitutive shedding of CX3CL1 via ADAM10
[27, 28]. Here, we show that, in astrocytes, inhibition of
p38 caused a significant decrease in the levels of sCX3CL1
induced by treatment with pro-inflammatory cytokines. It
is therefore reasonable to suggest that, in astrocytes, p38
via ADAM10 may enhance cleavage of CX3CL1 and/or
that a p38 signalling pathway is required for increased
production of this ligand.
Functions of astrocyte-derived CX3CL1
CX3CL1 signalling is crucial for proper development
during brain maturation [64], synaptic plasticity [65, 66],
neuroprotection [67, 68] and neurotoxicity [69, 70]. More
specifically, sCX3CL1 has the capability of enhancing
microglial response to CNS damage, thereby promoting a
pro-inflammatory environment [69]. However, membrane-
tethered CX3CL1 can also serve as an adhesion molecule,
thereby anchoring cells to the extracellular matrix and
preventing them from migrating [5]. In a myelin oligo-
dendrocyte glycoprotein (MOG)-induced experimental
autoimmune encephalomyelitis (EAE) rat model of MS,
neuronal CX3CL1 was reported unchanged and remained
at control levels [16]. However, at the sites of inflamma-
tion and surrounding active lesions, there is an increase in
astrocyte-associated CX3CL1 along with increased expres-
sion of CX3CR1 on microglia [16]. A possible role for
astrocyte-derived CX3CL1 may be to enhance CX3CR1
signalling on microglia and at the same time promote
levels of neuronal CX3CL1 as an attachment factor. This
dual role of CX3CL1 within the CNS may thus serve to
protect the surrounding tissue from damaged neurons
while also mobilizing microglia and astrocytes to eliminate
the damaged tissue.
Studies using CX3CL1 as a drug target—lessons learned
so far
CX3CL1 or CX3CR1 gene-disrupted animals are able to
mature to adulthood. However, CX3CR1−/− mice have
more synapses, a reduced number of microglia in the
hippocampus and delayed maturation of functional glu-
tamate receptors [64, 71]. Disruption to CX3CL1/CX3CR1
from conception also causes a differential response to
fractalkine treatment in comparison to wild-type ani-
mals following inflammatory and neurodegenerative in-
sults [67, 69]. In contrast, ADAM10 knockout animals
are embryonic lethal [72]. The genetic manipulation of
CX3CL1 signalling has to date led to contradictory
findings in mouse models of peritonitis regarding its
role in immune defence [73, 74]. In particular, studies
have shown that monocyte extravasation is not affected
in CX3CR1-deficient mice, suggesting that CX3CR1
signalling is not necessary for invading monocytes [73].
In contrast, CX3CR1-mediated signalling is demonstrated
to be essential for macrophages in mounting defence
against bacterial infection [74]. As the CX3CL1-CX3CR1
interaction appears exclusive, in contrast to other che-
mokines, this specificity has been considered as worthy
of exploitation for drug development. Previous studies
involving either CX3CL1- or CX3CR1-deficient mice
have, however, led to contradictory findings, where
CX3CL1 is suggested as neuroprotective or neurotoxic.
Studies, for example, on middle cerebral artery occlusion
(MCAO) in CX3CL1-deficient mice exhibited smaller in-
farct lesions and had lower mortality rates [75]. However,
administration of exogenous CX3CL1, to CX3CL1-
deficient mice, post ischemia, resulted in neurotoxicity
and increased infarct size [75]. Notably, these neurotoxic ef-
fects of CX3CL1 were not observed in CX3CR1-deficient
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mice [75]. Studies, in contrast, also show that CX3CL1 ad-
ministered to wild-type rats, just prior to MCAO, elicits
long-lasting neuroprotective effects [76]. In addition to this,
a narrow therapeutic concentration range for CX3CL1 ap-
pears to exist, where low concentrations are neuroprotec-
tive (15–70 pM) with higher levels (>150 pM) becoming
toxic [76]. Therefore, from these studies, it seems that the
concentration of CX3CL1 and its administration pre or
post insult, as well as activity of the endogenous CX3CL1
signalling pathway, determine the efficacy of CX3CL1 in
diseased models.
Conclusions
Here, we find that CX3CL1 shedding from astrocytes is
mediated by pro-inflammatory cytokines via an ADAM10-
dependent pathway, where p38 MAPKs as well as NF-kB
signalling may also play a role. This study suggests that the
regulation of CX3CL1 in glial cells may be an important
process during inflammatory events.
Additional file
Additional file 1: Figure S1. (A) Soluble fractalkine levels are
attenuated with ADAM10 inhibition following co-stimulation with TNF-α
and IFN-γ. Astrocytes (grown in standard media) were pre-treated with the
ADAM10 inhibitor (GI 254023X; 1 μM), for 30 min. Cells were then co-
stimulated with TNF-α (1 ng/ml) and IFN-γ (1 ng/ml) for 18 h. Quantification
of CX3CL1 ELISA revealed a significant decrease in soluble fractalkine when
pre-treated with the ADAM10 inhibitor. ###p < 0.001 compared to own
control and ***p < 0.001 compared to the matched treated group (one-way
ANOVA and Tukey’s post hoc test). Values expressed as averages ± SEM;
n = 4, duplicates. (B, C) Changes in the levels of sCX3CL1 are not associated
with cell death. Astrocytes were treated with (B) IL-1β (100 pg/ml), TNF-α
(10 ng/ml) and IFN-γ (10 ng/ml) or (C) a pan MMP inhibitor (MMP inhib.)
Marimastat (1 μM), specific ADAM10 inhibitor (GI 254023X; 1 μM) and the
p38 inhibitor, VX-702 (1 μM), all for 18 h. Cell viability was analysed using
MTT assay. A significant increase in cell viability is seen with IL-1β and TNF-α.
**p < 0.01 and ***p < 0.001; one-way ANOVA and Tukey’s post hoc test.
Values expressed as averages ± SEM; n = 5, triplicates. (D) Cytokines do not
increase protein levels of the active form of ADAM10. Astrocytes were
treated with IL-1β (100 pg/ml), TNF-α (10 ng/ml) and IFN-γ (10 ng/ml) for
18 h before western blotting (representative of three independent
experiments). In all cases, human astrocytes were serum starved for 3 h
before treatments.
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